In recent years, the rapid aging of the global population has led to an increase in cognitive disorders, such as Alzheimer's disease, presenting significant public health challenges. Although no effective treatments currently exist to reverse Alzheimer's, prevention and early intervention, including cognitive training, are critical. This report explores the potential of AI chatbots in enhancing personalized cognitive training. We introduce ReMe, a web-based framework designed to create AI chatbots that facilitate cognitive training research, specifically targeting episodic memory tasks derived from personal life logs. By leveraging large language models, ReMe provides enhanced user-friendly, interactive, and personalized training experiences. Case studies demonstrate ReMe's effectiveness in engaging users through life recall and open-ended language puzzles, highlighting its potential to improve cognitive training design. Despite promising results, further research is needed to validate training effectiveness through large-scale studies that include cognitive ability evaluations. Overall, ReMe offers a promising approach to personalized cognitive training, utilizing AI capabilities to meet the growing demand for non-pharmacological interventions in cognitive health, with future research aiming to expand its applications and efficacy.

Clinical trials need to recruit a sufficient number of volunteer patients to demonstrate the statistical power of the treatment (e.g., a new drug) in curing a certain disease. Clinical trial recruitment has a significant impact on trial success. Forecasting whether the recruitment process would be successful before we run the trial would save many resources and time. This paper develops a novel deep & cross network with large language model (LLM)-augmented text feature that learns semantic information from trial eligibility criteria and predicts enrollment success. The proposed method enables interpretability by understanding which sentence/word in eligibility criteria contributes heavily to prediction. We also demonstrate the empirical superiority of the proposed method (0.7002 PR-AUC) over a bunch of well-established machine learning methods. The code and curated dataset are publicly available at https://anonymous.4open.science/r/TrialEnroll-7E12.

Large Language Models (LLMs) and multi-agent systems have shown impressive capabilities in natural language tasks but face challenges in clinical trial applications, primarily due to limited access to external knowledge. Recognizing the potential of advanced clinical trial tools that aggregate and predict based on the latest medical data, we propose an integrated solution to enhance their accessibility and utility. We introduce Clinical Agent System (CT-Agent), a Clinical multi-agent system designed for clinical trial tasks, leveraging GPT-4, multi-agent architectures, LEAST-TO-MOST, and ReAct reasoning technology. This integration not only boosts LLM performance in clinical contexts but also introduces novel functionalities. Our system autonomously manages the entire clinical trial process, demonstrating significant efficiency improvements in our evaluations, which include both computational benchmarks and expert feedback.

The clinical trial process, also known as drug development, is an indispensable step toward the development of new treatments. The major objective of interventional clinical trials is to assess the safety and effectiveness of drug-based treatment in treating certain diseases in the human body. However, clinical trials are lengthy, labor-intensive, and costly. The duration of a clinical trial is a crucial factor that influences overall expenses. Therefore, effective management of the timeline of a clinical trial is essential for controlling the budget and maximizing the economic viability of the research. To address this issue, We propose TrialDura, a machine learning-based method that estimates the duration of clinical trials using multimodal data, including disease names, drug molecules, trial phases, and eligibility criteria. Then, we encode them into Bio-BERT embeddings specifically tuned for biomedical contexts to provide a deeper and more relevant semantic understanding of clinical trial data. Finally, the model's hierarchical attention mechanism connects all of the embeddings to capture their interactions and predict clinical trial duration. Our proposed model demonstrated superior performance with a mean absolute error (MAE) of 1.04 years and a root mean square error (RMSE) of 1.39 years compared to the other models, indicating more accurate clinical trial duration prediction. Publicly available code can be found at https://anonymous.4open.science/r/TrialDura-F196

Accurately predicting drug-drug interactions (DDI) for emerging drugs, which offer possibilities for treating and alleviating diseases, with computational methods can improve patient care and contribute to efficient drug development. However, many existing computational methods require large amounts of known DDI information, which is scarce for emerging drugs. In this paper, we propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs by leveraging the rich information in biomedical networks. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. The different edges on the biomedical network are weighted to indicate the relevance for the target DDI prediction. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.

Graph Neural Networks (GNNs) have shown success in various fields for learning from graph-structured data. This paper investigates the application of ensemble learning techniques to improve the performance and robustness of Graph Neural Networks (GNNs). By training multiple GNN models with diverse initializations or architectures, we create an ensemble model named ELGNN that captures various aspects of the data and uses the Tree-Structured Parzen Estimator algorithm to determine the ensemble weights. Combining the predictions of these models enhances overall accuracy, reduces bias and variance, and mitigates the impact of noisy data. Our findings demonstrate the efficacy of ensemble learning in enhancing GNN capabilities for analyzing complex graph-structured data. The code is public at https://github.com/wongzhenhao/ELGNN.

Knowledge graph (KG) embedding is a fundamental task in natural language processing, and various methods have been proposed to explore semantic patterns in distinctive ways. In this paper, we propose to learn an ensemble by leveraging existing methods in a relation-aware manner. However, exploring these semantics using relation-aware ensemble leads to a much larger search space than general ensemble methods. To address this issue, we propose a divide-search-combine algorithm RelEns-DSC that searches the relation-wise ensemble weights independently. This algorithm has the same computation cost as general ensemble methods but with much better performance. Experimental results on benchmark datasets demonstrate the effectiveness of the proposed method in efficiently searching relation-aware ensemble weights and achieving state-of-the-art embedding performance. The code is public at https://github.com/LARS-research/RelEns.